Tag Archive for: IND application

Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure

/in

MOJAVE study on track to start in Q2 2023 as planned, with initial data by year-end Randomized, controlled study in US seeking to confirm strong efficacy data seen in RED DESERT and SAHARA studies DSR well positioned as disease-modifying heart failure therapy Ghent, Belgium – 02 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), […]

Read more

Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure

/in

Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on 31 March 2023 for its second-generation […]

Read more